Pain reduction was a secondary endpoint. You can only do statistical analysis on a secondary endpoint if your study meets its primary endpoint. The FDA won't approve a treatment on a secondary endpoint if the primary endpoint is not met - they will just tell you to go off and run another Phase III trial and come back later.
This is exactly what happened in the CHF trial - a great result stuffed by terrible trial design. Heads need to roll.
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-174
-
- There are more pages in this discussion • 930 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
-0.015(1.51%) |
Mkt cap ! $1.124B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | 97.5¢ | $601.0K | 608.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 46246 | 97.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 98.0¢ | 50737 | 28 |
View Market Depth
| Last trade - 11.15am 20/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |